AMGEN Inc
AMGEN Inc (AMGN) Covered Calls
AMGEN Inc trades in the Drug Manufacturers - General industry with an IV Rank of 57.74%, average versus the past year. AMGN's highest covered call setup is the $500.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 8.15% out of the money with 4 days to expiration, a 8.16% return until expiration, and a 744.69% theoretical annualized return. Across the setups shown, annualized returns run from 203.69% to 744.69% at strikes between $472.50 and $540.00, with 4 to 25 days to expiration, as of Nov 16, 2026.
Read more
Running AMGN covered calls helps you generate income from AMGEN Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AMGN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AMGN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AMGN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AMGN covered call is worth writing.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
| 2026-11-20 | 4 | 500.00 | 8.15 | 0.05 | 0.32 | 3773.00 | 8.16 | 744.69 | -0.01 | +0.03 | 720 | 0.27 |
| 2026-11-20 | 4 | 490.00 | 5.99 | 0.10 | 0.60 | 2778.00 | 6.01 | 548.31 | -0.02 | +0.05 | 1,000 | 0.50 |
| 2026-11-20 | 4 | 485.00 | 4.91 | 0.50 | 1.75 | 2318.00 | 5.01 | 457.51 | -0.11 | +0.12 | 176 | 1.25 |
| 2026-11-20 | 4 | 480.00 | 3.82 | 0.65 | 4.00 | 1833.00 | 3.96 | 361.79 | -0.14 | +0.21 | 616 | 3.35 |
| 2026-11-20 | 4 | 477.50 | 3.28 | 0.36 | 2.00 | 1554.00 | 3.36 | 306.72 | -0.08 | +0.16 | 39 | 1.64 |
| 2026-11-20 | 4 | 475.00 | 2.74 | 1.25 | 2.58 | 1393.00 | 3.01 | 274.94 | -0.27 | +0.22 | 314 | 1.33 |
| 2026-12-04 | 18 | 520.00 | 12.48 | 0.09 | 1.49 | 5777.00 | 12.50 | 253.38 | -0.02 | +0.06 | 24 | 1.40 |
| 2026-12-11 | 25 | 540.00 | 16.80 | 0.06 | 1.64 | 7774.00 | 16.82 | 245.50 | -0.01 | +0.05 | 0 | 1.58 |
| 2026-11-20 | 4 | 472.50 | 2.20 | 1.06 | 2.99 | 1124.00 | 2.43 | 221.85 | -0.23 | +0.25 | 4 | 1.93 |
| 2026-11-27 | 11 | 490.00 | 5.99 | 0.70 | 4.00 | 2838.00 | 6.14 | 203.69 | -0.15 | +0.17 | 86 | 3.30 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank57.74% Moderate
- Market cap (M$)247,700
- 52 weeks high-5.38%
- 52 weeks low46.59%
- Analyst recommendationHold
2.66 - Target price$440.54
-3.80% below the current stock price - Dividend—
- Payout ratio66.92%
- Earnings date2027-02-02
- P/E26.56
- Future P/E18.27
- EPS (ttm)17.24
- EPS growth next 5 years7.13%
As of Nov 17, 2026